COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

Drug treatment of disseminated non small cell lung cancer  (NSCLC) is an actual  issue today.  Both clinical and economic efficacy analysis is needed for optimal therapy selection. We performed economic efficacy assessment of  gefitinib (G.)  therapy in patients with non operable NSCLC who hase no E...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: S. A. Protsenko, A. V. Rudakova, F. V. Moiseyenko, E. V. Levchenko, D. E. Matsko, A. О. Ivantsov, I. I. Semenov, A. G. Ievleva, N. V. Mitushkina, A. V. Togo, A. V. Novik, E. N. Imyanitov, V. M. Moiseyenko
Format: Article
Langue:anglais
Publié: Bashkir State Medical University 2017-01-01
Collection:Креативная хирургия и онкология
Sujets:
non-small-cell lung cancer
gefitinib
cost-efficacy analysis
Accès en ligne:https://www.surgonco.ru/jour/article/view/111
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires